The ABA is once again working on their list of the 100 best legal blogs and they want your advice on which blawgs you think they should include and / or what practice areas you’d like to see represented in the Blawg 100.

Use the Blawg 100 Amici form to tell us about a blawg——not your own——that you read regularly that you think other lawyers should know about. If there is more than one blawg you want to support, please send additional amici through the form. The ABA may include some of the best comments in their Blawg 100 coverage.

Editors make the final decisions about what’s included in the Blawg 100; this isn’t a scenario in which the blawgs that receive the most amici are the ones that make the list. See the amici form page for additional information about amici and Blawg 100 criteria.

Friend-of-the-blawg briefs are due no later than Friday, Sept. 9.

  Print This Post Print This Post  

The Biotechnology Industry Organization believes that fully realizing the promise of biotechnology requires a comprehensive national strategy that fine-tunes some policies and overhauls others.

BIO’s set of policy proposals address two vital needs: 1) the need to re-engineer the biotech economic model, and 2) the need to re-invent the idea-to-market pathway for biotech cures and other products.

Below is that plan:

Creating an FDA that Turns Hope into Cures

The American population is growing older — life expectancy is up by a decade since 1965 and 72 million Baby Boomers are about to enter Medicare. It has never been more critical to support an industry that is working to cure diseases and will impact all Americans by saving lives and dollars. It is imperative that the U.S. Food and Drug Administration (FDA) recognizes its national role in advancing innovation by reviewing innovative products in a timely manner and promoting a consistent and science-based decision making process that is reflective of patient needs.. By facilitating the creation of a 21st century FDA and more effective clinical research and development processes, the proposals below help establish a clear and effective pathway for turning hope into cures.

Elevating FDA and Empowering Operational Excellence

Include Innovation in FDA’s Mission Statement

FDA must have both the capacity and commitment to incorporate the latest scientific advances into its decision-making so that processes can keep pace with the tremendous potential of companies’ cutting-edge science. Congress can help encourage medical breakthroughs by updating FDA’s mission to incorporate modern scientific tools, standards, and approaches.

Establish a Fixed Term of Office for the Commissioner of Food and Drugs

Encouraging consistent and stable leadership at FDA — with protection from the political influence that typically occurs during a Presidential Administration transition — would better equip the agency to fulfill its mission as a science-based regulator to promote and protect the public health. The law should be amended to provide that the President appoint the Commissioner to a six-year term of office. Once confirmed, the Commissioner would be removable by the President only for pre-specified reasons — neglect of duty, malfeasance in office, or an inability to execute the FDA’s mission.

Grant FDA Status as an Independent Agency

The FDA regulates nearly a quarter of the consumer goods supplied to the American public. As such, the agency should have the same authorities to make budget, management, and operational decisions as afforded other independent agencies such as the Environmental Protection Agency. This would empower the agency to work more effectively with the President and Congress to carry out its mission to promote and protect the public health, and would also enhance the agency’s ability to obtain quality and consistent leadership.

Establish an External Management Review Board for FDA

The FDA is a large, complex organization. Amending the law to establish a Management Review Board (consisting of experienced external advisors) that conducts periodic reviews of FDA’s management and organizational structure and provides fresh, visionary, and independent thinking and recommendations on how to improve FDA’s ability to fulfill its mission could help the agency address its chronic operational challenges.

Advancing Regulatory Science & Innovation

Release FDA Funding to Support Regulatory Science Public-Private Partnerships

Congress established an independent, nonprofit foundation to support public-private partnerships for the purpose of advancing FDA’s mission through, for example, the formation of collaborations to advance the use of biomarkers, surrogate markers, and new trial designs to improve and speed clinical development. However, Congressional appropriations bills have subsequently restricted FDA’s ability to transfer federal funding to the foundation. These funding restrictions should be lifted so that the foundation can fulfill its intended purpose and promise

Create an FDA “Experimental Space” to Pilot Promising New Scientific and Regulatory Approaches The FDA has developed several initiatives to advance regulatory science. However, FDA’s ability to incorporate modern science into its regulatory processes has been limited because there is no entity within the agency with unified responsibility for systematically analyzing the findings and recommendations from these initiatives, and with clear authority to pilot promising scientific and regulatory approaches. An FDA “Experimental Space,” led by a new Chief Innovation Officer, should be established with the responsibility and authority to ensure that promising new approaches are integrated into agency operations at all levels.

Enhance FDA’s Access to External Scientific and Medical Expertise

Scientific and medical knowledge, techniques, and technology are advancing at a more rapid pace today than at any other time; however, FDA’s capacity to access information about these advances has not kept pace despite the widespread perceptions of the agency as the global standard bearer for science-based regulatory review. It is essential that FDA’s access to scientific and medical advice be enhanced by improving the operations of FDA Advisory Committees, establishing Chief Medical Policy Officers in the immediate offices of the Center Directors, and providing FDA staff with additional avenues for accessing external scientific and medical expertise.

Enabling Modernized Patient-Centric Clinical Development

Increase Access to Innovative Therapies through Progressive Approval

Patients, particularly those with illnesses for which no adequate therapy exists, want access to promising new therapies earlier in the drug development process. Expanding and improving the accelerated approval pathway into a progressive approval mechanism would provide patients timely access to needed therapies, while helping ensure smaller biotech companies are able to maintain operations through extensive phase III clinical testing. Only innovative products for unmet medical needs, significant advances to standard of care, targeted therapies, or those that have been approved by the European Medicines Agency or other mature regulatory agencies would qualify for progressive approval.

Of the 54 orphan drugs approved between
1998 and 2007,
58% were discovered and
developed by biotech companies.

Nature Reviews/Drug Discovery, November 2010

Empower FDA to Utilize a Weight-of-Evidence Approach to Establish Effectiveness

FDA is statutorily required to approve applications for new drugs when they have been demonstrated to be safe and there is “substantial evidence” that the new drug is effective. FDA typically requires two “adequate and well controlled” studies under this standard.

A weight-of-evidence approach to data analysis, however, allows the decision-maker to look at all data and information, whatever its value, and give each appropriate consideration.

Between 1999 and 2005, the average length
of clinical trials
grew by 70%. Currently, the
average time from discovery of a drug
to getting it to patients is
10 to 15 years.

Source: Tufts Center for the Study of Drug Development

Leverage Electronic Health Records to Facilitate Clinical Research

Using health information technology (IT) such as electronic health records in clinical research will improve and speed up the drug development process while decreasing costs. However, there are significant barriers preventing widespread use of health IT in clinical research, including slow adoption by providers and lack of standards. To help remove those barriers, Congress should create a Clinical Informatics Coordinator in the Office of the Commissioner of Food and Drugs charged with developing processes to validate and encourage the use of health IT in clinical research and establishing pilot projects to use health IT in clinical research.

Require FDA to Disclose to Companies Reasons for Non-Approval

Current law implies that new drug and biologic applications must either be approved or denied. In practice, however, there is a third response in which FDA neither approves nor officially denies the application (which would require FDA to give the company specific procedural rights such as a hearing); rather, FDA finds the application to be incomplete in some way and therefore ineligible for approval. When FDA makes such a finding, it should communicate to the company in clear terms why risk was determined to outweigh benefits and why tools such as Risk Mitigation and Evaluation Strategies are insufficient (in addition to indicating what must be done to address any deficiencies). This will help ensure a consistent and transparent risk-benefit evaluation and provide the company with better information on what, if any, additional studies are required to achieve approval.


See also:

BIO: Unleashing the Promise of Biotechnology (pt.1)
BIO: Unleashing the Promise of Biotechnology (pt.2)
BIO: Unleashing the Promise of Biotechnology (pt.3)

  Print This Post Print This Post  

Sarah Randag of the ABA Journal is hosted Blawg Review #314 in an edition she calls LawLawpalooza! hosted this week’s Blawg Review in conjunction with the 2011 ABA Annual Meeting in Toronto.

Curiously, they were not actually blawging from Canada as they were in Chicago over the weekend noticing the train riders coming in and out of the Loop — many who were among the 250,000 people going to and from the Lollapalooza music festival.

As Lolla ticketholders must choose between bands playing simultaneously, the lawyers at the ABA conference, with some 1,400 legal programs, including business meetings for association entities, do the same and work their way around five or 10 venues for their own LawLawpalooza.

So, check out the LawLawpalooza Blawg Review and see what’s happening around the blawgosphere.  We especially enjoyed the posting about the ABA Expo, where blogger Carolyn Elefant of My Shingle was with Social Media for Lawyers co-author Nicole Black, signing copies of their book:

Social Media for Lawyers: The Next Frontier, American Bar Association (June 16, 2010), described as “a cutting-edge guide that shows lawyers how to use a practical, goal-centric approach to social media. By enabling lawyers to identify the social media platforms and tools that fit their practice, lawyers can implement them easily, efficiently, and ethically. Written by two lawyers, this book is designed with both the novice and advanced user in mind.”

They wrap up the book noting that “Law firms and lawyers who turn a blind eye to technology do so to their own detriment, and their failure to acclimate to rapid technological change is going to catch up with them in 2010 and beyond.”



  Print This Post Print This Post  

According to The Wall Street Journal, Mark Bowden, the U.N.’s top official in charge of humanitarian aid in Somalia, said the country “is facing its worst food security crisis in the last 20 years. This desperate situation requires urgent action to save lives…It’s likely that conditions will deteriorate further in six months.”

More than 10 million people across the Horn of Africa are in dire need of humanitarian assistance due to a deadly combination of the worst drought conditions in 60 years, escalating food prices and armed conflict. Two million children are at risk of starvation in Kenya, Ethiopia, Djibouti and Somalia. In southern Somalia alone, the crisis has killed 29,000 young children in the last 90 days.

By making a donation and spreading the word about the crisis, you will help make an impact. Here are five organizations that are on the ground in East Africa that need your support.

1. International Rescue Committee:  The International Rescue Committee is scaling up relief efforts to aid people devastated by the drought. Some of their work in this region includes providing new arrivals with medical screenings and fortified food for malnourished young children in Dadaab refugee camp, northeastern Kenya.


2. World Food Programme: The World Food Programme is the world’s largest humanitarian aid organization fighting hunger. Your emergency donation will help them reach more people on the edge of survival, specifically women and children.


3. Oxfam: Oxfam is aiming to reach 3 million people with water, sanitation services, and food. A donation of $50 will provide 200 people a day’s supply of clean water and a $100 donation will feed a family of six for two+ weeks.


4. Save the Children: Donate a dollar a day for 100 days to help a child through the drought.


5. CARE: A tax-deductible gift will help CARE address global hunger, improve healthcare and create economic opportunity in Somalia, Kenya and other poor countries around the world.


6. World Vision:  World Vision is a faith-based organization that strives to eliminate poverty and injustice. Text 4AFRICA to 20222 on your mobile phone to donate $10 to support the emergency relief efforts.


7. Mercy Corps: Mercy Corps is responding to the drought in East Africa with emergency operations in northeastern Kenya and plans to build on existing work in Ethiopia and Somalia. Through emergency food distributions, clean water delivery and cash-for-work activities, they have helped 150,000 people thus far.


Image source: SAACID-ORG

  Print This Post Print This Post  

The Biotechnology Industry Organization believes that fully realizing the promise of biotechnology requires a comprehensive national strategy that fine-tunes some policies and overhauls others.

BIO’s set of policy proposals address two vital needs: 1) the need to re-engineer the biotech economic model, and 2) the need to re-invent the idea-to-market pathway for biotech cures and other products.

Below is that plan:

Policies to Stimulate a Bio-based Economy

The “Bio-based Economy” refers to economic activity and jobs generated by:

  • the use and conversion of agricultural feedstocks to higher value products;
  • the use of microbes and industrial enzymes as transformation agents or for process changes; and
  • the production of bio-based products and biofuels.

The proposals below seek to elevate the concept and awareness of the bio-based economy and highlight the outstanding job creation and rural/rust belt economic development potential of industrial biotechnology and biorefinery commercialization.


Reauthorization and Enhancement of the Biomass Crop Assistance Program (BCAP)

BCAP is the key program encouraging and facilitating farmers and landowners to produce new purpose grown energy crops (PGECs) for advanced biofuels and bio­based products. Beyond reauthorizing the program through December 2017, we can further enhance it by:

  1. Ensuring funds are directed primarily to production of next generation crops for biofuels and bioenergy;
  2. Establishing a dedicated funding mechanism for awarded contracts;
  3. Providing for eligibility of non-food Title I crops; and
  4. Clarifying eligibility of certain other PGECs.

Federal Crop Insurance for Purpose Grown Energy Crops Currently, there is no formal federal crop insurance program available to producers of new PGECs. Requiring the U.S. Department of Agriculture’s Risk Management Agency to finalize its ongoing feasibility study of developing a crop insurance program for certain biofuels and bio-product feedstocks – and appropriately funding the Commodity Credit Corporation -would enable the formal establishment of such a program.

Feedstock Sustainability Enhancement Grants The continued development of domestic sources of energy, including for biofuels and renewable chemicals, depends upon the sustainable availability of consistent, high yield, good quality feedstocks. Establishing a grant program through the U.S. Departments of Agriculture and Energy would enable the funding of demonstration projects that utilize practices to enhance biofuel and bioenergy feedstock sustainability.

Codifying and Expanding the Definition of Renewable Chemicals

Many of the programs in the 2008 Farm Bill’s Title IX renewable energy programs are not available to renewable chemicals and bio-based products, despite their profound potential benefits to rural America. Codifying a more expansive definition of eligible renewable chemicals and bio-based products would enable enhanced participation of renewable energy projects in programs such as the Biorefinery Assistance Program and Rural Energy for America Program.


Tax Credit for Production of Qualifying Renewable Chemicals

Renewable chemicals and bio-based plastics represent an important technology platform for reducing reliance on foreign oil, creating green U.S. jobs, increasing energy security, and reducing greenhouse gas emissions. By providing a renewable chemicals tax credit in the form of a federal income tax credit for domestically produced renewable chemicals, Congress can create jobs and other economic activity and can help secure America’s leadership in the important arena of green chemistry. The credits would be general business credits available for a limited period per facility, and taxpayers would be subject to a competitive application and review process to ensure conformance with legislative intent.

Tax Code Reforms to Increase Availability of Advanced Biofuels and Facilitate Energy Security

Current tax law on advanced biofuels does not provide an ordered pathway toward U.S. energy security. Policymakers can help incentivize bringing commercial volumes of affordable advanced biofuels to market in the near term by amending the current tax code to:

  1. Extend the Cellulosic Biofuel Production Tax Credit through 2016 and add eligibility for algal biofuels;
  2. Allow advanced biofuel facility developers the option of electing to receive an investment tax credit;
  3. Provide for eligibility of biorefinery retrofit projects;
  4. Provide eligibility to federal Section 1603 Grants in Lieu of Tax Credits program; and
  5. Extend and expand eligibility for cellulosic biofuel property accelerated depreciation.


Strategic Biorefinery Initiative and Offtake Authority

Development of domestic sources of renewable biofuels and bio-based products would yield substantial energy security benefits. The Department of Defense is uniquely positioned to help accelerate production and deployment of these vital products through establishment of a Strategic Biorefinery Deployment Program to finance construction of the first five commercial military advanced biofuel biorefineries. Under such a program, a biorefinery “fly-off” would identify and fund construction of the most promising projects. The authority to enter into long-term (up to 15 years) offtake agreements for procurement of advanced biofuels for military use would further enhance the Department of Defense’s ability to facilitate development of domestic sources of renewable biofuels.


Repurpose and Retrofit Grant Program for Expanding Production of Advanced Biofuels

Repurposing or retrofitting existing idled or underutilized U.S. manufacturing facilities is one of the most time and cost effective ways to build out the advanced biofuels and renewable chemicals sector. Establishing a federal matching grant program through the U.S. Department of Energy to fund up to 30% of costs would facilitate investments in such repurposing and retrofitting projects while helping to rapidly expand U.S. production capacity for advanced biofuels and renewable chemicals.

Synthetic Biology for Enhanced Sustainability of Biofuels and Renewable Chemicals

The advancing field of synthetic biology has the potential to enhance greatly both the economic and environmental sustainability of fuels and chemicals manufacturing. Establishing a Synthetic Biology Research and Development Grants Program through the U.S. Department of Energy would support research that could help enable the cost-effective sustainable production of advanced biofuels, renewable chemicals and other technologies that reduce or minimize greenhouse gas emissions, including biological processes for removing carbon dioxide from the atmosphere.

Industrial Bioprocess R&D Program

The use of industrial biotechnology for the production of renewable chemicals and bio-based products is enabling dramatic improvements in industrial energy efficiency as well as a host of renewable alternatives to traditional petrochemical-based products. Establishing an Industrial Bioprocess Research and Development program through the Department of Energy would fund projects in industrial biotechnology for renewable chemicals, bio-based products, and renewable specialty chemicals.

See also:

BIO: Unleashing the Promise of Biotechnology (pt.1)
BIO: Unleashing the Promise of Biotechnology (pt.2)
BIO: Unleashing the Promise of Biotechnology (pt.4)

  Print This Post Print This Post  

When you’re networking with more than 15,000 of your closest friends at the BIO International Convention in Washington, DC, you’re bound to meet an interesting person or two.  I met more than that.

At this year’s convention, I met either the most interesting person I’ve ever met or the craziest person I’ve ever met.  Or both.  Meet Robert Cantrell of Think IP Strategy.

PB: Robert, you have been an IP Strategist, MBA, author on business and military strategy, a professional shark photographer and now a documentarian of the world’s most dangerous sharks.  Just what haven’t you done?

RC:  Hi Stephen.  I have not and probably will never go bungee jumping off a bridge.  Every risk needs to have a purpose.

PB: So, you were sitting around one day and you said, “Hey, I could make a movie about swimming with dangerous sharks.”  How did that come about and did your friends and family think this was a good idea?

RC:  This part was easy.  My friends and family are highly supportive because they have seen my still photography work with sharks and have wanted me to combine that with my writing.  They had been encouraging me to do this.

PB: Is there something about the Oceanic Whitetip Shark that made you want to swim with them in the dark?

Robert CantrellRC:  Conventional wisdom was that you do not dive with oceanic whitetip sharks at night.  Jacques Cousteau called them “The most dangerous of all sharks.”  These are the sharks that historically have shown up at open ocean disasters such as the sinking of the USS Indianapolis in 1945, made famous by the monologue of Quint (Robert Shaw) about living through the experience in the movie Jaws.

There is a famous night sequence in the 1970 shark documentary Blue Water, White Death, by Peter Gimbel, that showed multiple oceanic whitetip sharks feeding at night.  Peter’s team shot that sequence from within shark cages.  Peter said that he regretted that the team had not left the cage at night…they had been the first team to venture out during the day.  That documentary had an influence on me growing up, and this was an opportunity to answer that regret as best we could with multiple oceanic whitetip sharks at night.

PB: How long did it take to prepare for the project?

RC:  It took ten months from concept approval in August 2010 to wrapping up filming in June 2011.  Post-production is in progress now.

PB: Did you have certain expectations going into this project? Did you have anything specific in mind that you knew you wanted to include in the day you filmed?

RC:  Things happened remarkably as expected, even with challenging weather, which is a big wildcard.  I had been on site with the oceanic whitetip sharks before, so I knew what everything was going to look like and how the sharks were likely to behave.  I also knew everyone I asked to participate in the shoot – 10 people in total from camera to crew – and we had people predisposed to work well with each other and offer creative suggestions.  We had three contingencies: 1. A story line if we succeeded with the night dive.  2. A story line if the night dive did not happen.  3. An alternative tiger shark shoot if we found no oceanic whitetip sharks at all.  As it was, we shot a rather extensive storyboard plan pretty much as written, with only a few additions and deletions as new or better opportunities presented themselves.

Now, emulating movie making, we want to make sure that every clip of dialog we use, every narration, and every picture shown has a purpose to drive the story forward.  We have an overabundance of material will help us in this – many documentaries actually find themselves short of material.

PB: What is the most amazing thing you’ve learned working on All Fins On?

RC:  This shoot reinforced several strategy principles I teach in my strategy courses – and itself quite resembled the best part of small unit military planning I used to do, albeit with multiple cameras instead of weapons.  The whole planning and operation was an exercise in, piece-by-piece, reducing the uncertainties I could control so that we could focus on the uncertainties we could not control…such as whether we would find any oceanic whitetip sharks at all.  It became organized flexibility at its best.

PB: It’s clear that you have a genuine appreciation of sharks that seems to come from personal experience. What kind of animals did you grow up with, and what kind of relationship did you have with them?

RC:  We always had a family dog, and I have often had tropical fish.  Since I left college, I have been on the road too much to make keeping a dog practical, however, the fish do fine with an automatic feeder.  The more I see the wild, however, the more I regret that any animal that would not voluntarily stick around should have any confines at all…including people.

PB: Veteran nature film producer Chris Palmer wrote a book entitled Shooting In The Wild.  He takes an in-depth look at the world of wildlife filmmaking to expose the ethical dilemmas faced by filmmakers who manipulate, fabricate, and deceive – all in the name of presenting nature “realistically.” The book has been generating a fair amount of media buzz with its recounting of staged animal sequences to coax certain behaviors, use of captive animals from animal farms or zoos, and even animal abuse – all for the sake of “getting the shot.”  Did you face such dilemmas in shooting All Fins On?

RC:  I read this book just prior to the shoot.  To bring the oceanic whitetips around, we necessarily had to offer them an incentive.  While we did not feed them per say, we did put crates with fish parts in the water to provide a scent for them to investigate.  An occasional scrap would float free that they would snap up.  Given that scent, the sharks were always free to swim in, investigate us, and either stay around or leave as they chose.  One individual shark stayed with us for four days straight and participated in our night dive.

PB: As you know, this is Shark Week on the Discovery channel. Do you think these kinds of ratings boosting, shark as a scary, man-eating menace shows hinder conservation efforts? And do you watch?

RC:  Here you get to a central point of this documentary.  The easiest way to make a shark documentary to generate high ratings is to talk about one or more shark attacks, do a few interviews, recreate the scene, add a few shark clips, and done.  The second easiest is to go to tried and true shark hot spots and see whether sharks will eat this or that.  Discovery’s dilemma is that they are a commercial enterprise, and like it or not, shark conservation movies don’t sell well to the general public.  We hope to offer an alternative anchored on solid storytelling and a cinematic presentation that provides the commercially saleable tension and fear that many people want with their shark stories along with a positive message that we actually need sharks for healthy oceans and our own survival as a species.  Even a survivor of the USS Indianapolis we interviewed who lost a good friend to a shark right beside him thought that for the generations following to understand their story, they also need to see their shark.

PB: Finally, says that Shark Attack 3: Megalodon is the worse shark movie ever.  Your thoughts?

RC:  I have not seen this movie … if it went beyond Jaws 4, that is actually a cinematic accomplishment.  For anyone who does not know, Megalodon is the giant extinct predatory shark known by the hand sized fossil teeth.

I work with a literary manager/producer in California, Ken Atchity, who helped one of his clients sell another Megalodon story, Meg, optioned to Hollywood for 1 million dollars. He is co-owner and manager of the Louisiana Wave Studio where an upcoming 3D shark thriller was filmed that will no doubt pack theaters called Shark Night 3D. In contrast, a single night showing of the well-done shark conservation movie, Shark Water, in Washington D.C. attracted all of four people, including me. That is the challenge that makes this project particularly exciting and important. I don’t think it has to be an either or proposition … I believe you can succeed with sharks commercially if you offer a realistic presentation of the shark and build it around a compelling and true story. Sharks are not monsters out to get us, nor are they benevolent beings. They are just sharks. Shark Night 3D may be so over the top, then, that people can enjoy the terror of the movie without seeing it as real life … a factor in Jaws since that movie did make it all seem too real for many people.

PB: Robert, thank you so much for your time today.  Good luck with your movie.

RC:  Thank you.


Robert Cantrell has written a number of articles and papers on intellectual property.  This includes his recently published book, Outpacing the Competition: Patent-Based Business Strategy (Robert Cantrell: Wiley 2009).  This book blends patent strategy, business strategy, and classical strategy into a comprehensive whole, with the overall theme that those businesses capable of proficiently assessing their situations, deciding on courses of action, and taking action, win most competitive contests.

Several of his written works are in use at the national and service war colleges as well as in the intellectual property field to include the top selling book Understanding Sun Tzu on the Art of War.

Robert is the founder of Center For Advantage, a provider of tools for strategy, innovation, and sales workshops, training, and problem solving. He is on the faculty of Patent Resources Group, where he teaches Patent Strategy for Business. And he was last seen developing a cure for cancer.

  Print This Post Print This Post  

The Biotechnology Industry Organization believes that fully realizing the promise of biotechnology requires a comprehensive national strategy that fine-tunes some policies and overhauls others.

BIO’s set of policy proposals address two vital needs:

1) the need to re-engineer the biotech economic model, and
2) the need to re-invent the idea-to-market pathway for biotech cures and other products.

Below is that plan:

Small Business Tax Incentives

Removing Financing Restrictions: Section 382 Net Operating Loss Reform

Section 382 of the Internal Revenue Code restricts the usage of net operating losses by companies that have undergone an “ownership change.” However, small biotech companies are unintentionally caught in its scope due to their reliance on outside financing and investment deals. Exempting net operating losses generated by qualifying research and development by a small business from Section 382 and redefining “ownership change” to exclude certain qualified investments (like those in rounds of venture financing) would enable small biotech companies to increase their value when preparing for mergers or initial public offerings.

Nearly a third of small U.S. biotech companies
have been approached to move their R&D
offshore, and CEOs named China
and India as two prime destinations.

Source: Therapeutic Discovery Project Post-Award Survey.
Penn Schoen Berland, prepared for BIO.

Incentives for Non-Investor Capital

Increasing R&D Investment: Tax Holiday on Repatriated Investments in Small Biotechs Many small biotechnology companies rely on collaborations with large multi-national corporations to fund their research and development. A repatriation tax holiday on funds brought back to the United States from abroad would incentivize these large companies to repatriate earnings they are holding overseas and give them the ability to invest in and collaborate with small biotechs conducting groundbreaking research here at home.

Rewarding Innovative R&D Businesses: U.S. Innovation Box

Many Western European countries have implemented reduced corporate tax rates on income stemming from certain types of intellectual property. Allowing for a reduced corporate rate on this type of income would make investment in U.S. biotechnology more attractive and competitive, and would provide innovative companies with a greater return on their R&D expenses — allowing them to undertake more research projects here in the United States.

Most big pharmaceutical companies have
significant cuts to research and
development activities.

Source: Reuters: “Analysis: Big Pharma strips down
broken R&D engine,” 11 May 2011.

Supporting Industry Collaborations: Section 197 Amortization Reform

Small biotechs typically have intangible assets that are amortizable under Section 197 of the Internal Revenue Code. Reforming that law to provide for faster cost recovery for intangible assets acquired by investors would encourage large company investors to invest at an earlier stage in small biotech companies’ research.


BIO: Unleashing the Promise of Biotechnology (pt.1)
BIO: Unleashing the Promise of Biotechnology (pt.3)
BIO: Unleashing the Promise of Biotechnology (pt.4)

  Print This Post Print This Post  

Despite the urgent need for scientific breakthroughs in biotechnology, current government policies are holding back the potential and promise of the scientific potential that resides in the thousands of biotech companies.

The Biotechnology Industry Organization had looked at the changes to our policy environment that would incentivizes companies to develop the breakthrough cures, treatments, enhanced agricultural products, vaccines and biofuels.
BIO notes that biotech research and development is a particularly high-risk undertaking because of the substantial start-up costs, lengthy experimentation period, and possibility that the technology will not prove viable.

BIO believes that fully realizing the promise of biotechnology requires a comprehensive national strategy that fine-tunes some policies and overhauls others.

BIO’s set of policy proposals address two vital needs for ensuring biotechnology innovation and industry growth:

1) the need to re-engineer the biotech economic model, and

2) the need to re-invent the idea-to-market pathway for biotech cures and other products.

Below is that plan:

I. Promoting Investment in Innovation

Congress has historically provided tax incentives to high-risk endeavors (such as oil and gas exploration, alternative energy, and high-tech start-ups) as a means for encouraging new investment. However, current tax law does not do enough to foster investment in health care, green technology, or energy-focused biotechnology companies. Given the economic and societal benefits of ensuring a robust biotech industry in the United States, it is imperative that Congress and the Administration adopt policies that recognize the unique financial structure and capital needs of biotech companies.

Features Of The Typical Biotech Company
• Unprofitable—3 or more years away from having product revenue
• Private company (70% of the biotech industry is private)
• Fewer than 50 employees
• Completed one round of venture capital financing

The proposals are designed to incentivize investors, strengthen small business, and promote innovation.

Small Business Investor Incentives

Incentivizing Small Biotech Investment: Angel Investor Tax Credit

Modeled after numerous state programs, a federal Angel Investor Tax Credit would provide an incentive for individuals to invest in emerging biotech companies researching innovative technologies. To be eligible, investors would have to invest in a company with fewer than 500 employees performing qualifying research. The credit would be equal to 50% of their investment.

Worldwide, 35% of pharmaceutical companies
outsourced projects to Asia in 2009, with
China and India the top two destinations.
Source: “Annual Outsourcing Survey,” Contract Pharma (2009)

Stimulating Private Capital for Biotechnology: R&D Partnership Structures

Due to the lengthy drug development process, small biotechnology companies often have difficulty obtaining early-stage financing for their research and development and, because they are not yet profitable, are unable to immediately use their tax assets (i.e., tax credits and losses) to offset income. The development of new partnership structures that allow a biotech company’s investors to offset their income with the company’s tax assets would significantly stimulate much needed private investment in biotechnology.

Improving Capital Gains Treatment for Small Businesses: Section 1202 Reform

Section 1202 of the Internal Revenue Code provides for a reduced capital gains rate for qualified investments in certain small business stock. However, due to the valuable intellectual property and successive rounds of financing inherent in biotech innovation, biotech companies do not meet the definition of qualified small businesses under Section 1202. Modifications to the small business definition and other changes in Section 1202 would encourage investment in research performed by capital-intensive, small biotech companies.

In India, the Biotech Industry Partnership
program provides grants and soft loans to
companies conducting high-risk research, which
has fostered a 20% annual growth rate.
Source: Global Biotechnology Report 2008, Ernst & Young

Doubling Private Funding: Matching Grants for Investments in Start-Ups

A small business early-stage investment program would provide matching grants to venture capitalists that specialize in funding small, innovative companies. The government grants would match investments in targeted small businesses, including emerging biotech companies, essentially doubling their financing by enabling seed financing to spur further investment.

Venture Capital Investing In Biotech Has Declined and Remains Largely Stagnant
• According to Pricewaterhouse Coopers, the first quarter of 2011 marked
the fewest biotech venture deals of any quarter since 2003.
• The average deal for the first round of funding in the first quarter of 2011
was $2.2 million, the smallest average size for such deals since 2005.
• In 2007, U.S. biotech companies raised $5.2 billion in venture financing.
In 2010, the industry raised just $3.7 billion in venture capital, 30% less than 2007’s total.
• The troubled IPO market and financial crisis have contributed to
the reduced size of the United States biotech industry.
The number of public biotech companies in the U.S. has decreased by 25% since January of 2008.


BIO: Unleashing the Promise of Biotechnology (pt.2)
BIO: Unleashing the Promise of Biotechnology (pt.3)
BIO: Unleashing the Promise of Biotechnology (pt.4)

  Print This Post Print This Post